6th June 2013
Alliance Pharma acquires global rights to Syntometrine from Novartis
Alliance Pharma plc has acquired all existing rights to SyntometrineTM from Novartis AG and Novartis Pharma AG (together "Novartis") for a consideration of US$11.5 million.
Read this article
7th May 2013
Graham Cox to join eZono as CEO
eZono’s supervisory board has appointed Graham D. Cox as the company’s Chief Executive Officer effective 1st June 2013. Mr. Cox will succeed Allan R. Dunbar, co-founder and acting CEO of eZono, who remains with the company as Chief Commercial Officer.
Read this article
29th April 2013
Cara partners with Maruishi for Japanese rights to CR845
Cara Therapeutics, Inc. and Maruishi Pharmaceutical Company, Ltd. (Maruishi) today announced that they have entered into a License Agreement providing Maruishi with exclusive rights to develop, manufacture and commercialize Cara’s lead analgesic drug candidate, CR845, for acute pain and uremic pruritus in Japan.
Read this article
22nd April 2013
Horizon Discovery Announces Oncology Drug Discovery Collaboration with AstraZeneca
Horizon Discovery (Horizon) and AstraZeneca have entered into an exclusive collaboration and license agreement to explore Horizon’s first-in-class kinase target programme, HD-001, as a means of developing novel therapies for multiple cancer types.
Read this article
19th March 2013
Biovex Phase III trial meets primary endpoint
• Biovex’s acquirer Amgen announces Phase III trial of talimogene laherparepvec in melanoma has met its primary endpoint
Read this article
News Archive
Last 5 Articles | Next 5 Articles
22nd November 2011Health Information Announces Investment from MVM Life Science Partners
Health Information, the dominant provider of point of dispensing messaging in the UK, announces that it has secured a first round of funding from MVM Life Sciences LLP (“MVM”). MVM is a leading EU/US life science venture capital fund with $500m under management. This financing will support the continued development of the company’s pharmacy network, strengthening of the pharmaceutical sales team and preparations for EU roll-out of the business.
Health Information is a pioneer in this field, and is launching first-to-market clinical messaging services within 40% of retail pharmacies and 50% of hospital pharmacies. Over the last three years Health Information has completed over 40 customer projects for 18 of the top 20 UK pharmaceutical companies.
Health Information’s mission is to enhance patients’ lives by enabling point of dispensing intervention. It has already supported millions of patients, and continues to pioneer new and innovative services, via its network of thousands of independent and hospital pharmacies.
Through its point of dispensing messaging, Health Information has repeatedly proven that it supports patients understanding of their conditions, improves compliance with their medication and drives strong growth of customer brands in a measurable fashion.
Mr Thomas Casdagli, from MVM, has joined the board. Mr Casdagli has over 9 years of healthcare investment experience and currently serves as a Member of the Boards of Alliance Pharma plc and Lombard Medical Technologies plc.
Mr Casdagli said, “We are delighted to be making this investment. Health Information’s position in the market and track record of ground-breaking, effective innovations, represent a unique opportunity. We are excited about the prospects for growth, both within the UK and continental Europe.”
Dr Grace Lomax, Founder of Health Information said “We are delighted to partner with a specialised healthcare investor like MVM to support the continuing growth of our business. MVM clearly recognise the value of clinical messaging in pharmacy and its ability to provide our partners with superior returns than traditional marketing and sales approaches.”
| Associated Links Visit Health Information Limited |
Downloads Full Press Release |